Krystal Biotech, Inc.
KRYS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001711279
In the last 90 days, Krystal Biotech, Inc. insiders filed 0 open-market purchases and 3 sales; 424 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $9.08B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $26.2M in total
- 3
- 13F holdersQ2 2026, +56 vs. previous quarter
- 424
- 13F valueReported value at the end of Q2 2026
- $11.1B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $389.1M
- +33.9% year over year
- Net income, FY2025
- $204.8M
- +129.7% year over year
- Free cash flow, FY2025
- $188.9M
- +58.5% year over year
- Revenue, Q3 FY2026
- $127.3M
- +30.2% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 3.04M
- Shares sold short
- Change
- +108.8K
- +3.7% vs. previous
- Days to cover
- 12.23
- At average daily volume
Superinvestors holding KRYS, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding KRYS at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Krystal Biotech, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 (view filing)7:15 PM ET | Sep 4 | Same day | Krishnan SumaPresident, R&D | SSale | −25.0K | $359.32 | −$8.98M | −1.9%1.30M after | 13 lots10b5-1 |
| Sep 4, 2026 (view filing)7:14 PM ET | Sep 4 | Same day | Krishnan Krish SPresident and CEO | SSale | −25.0K | $359.32 | −$8.98M | −1.8%1.35M after | 13 lots10b5-1 |
| Aug 14, 2026 (view filing)6:22 PM ET | Aug 14 | Same day | Rossi Dino ADirector | SSale | −25.0K | $329.12 | −$8.23M | −33.3%50.0K after | 8 lots |
| Jun 26, 2026 (view filing) | Jun 25 | 1 day | Thomas John CharlesEVP, General Counsel | SSale | −1.00K | $347.27 | −$347.3K | −100.0%0 after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 4 | 1 day | Krishnan SumaPresident, R&D | SSale | −25.0K | $308.12 | −$7.70M | −1.8%1.38M after | 11 lots10b5-1 |
| Jun 5, 2026 (view filing) | Jun 4 | 1 day | Krishnan Krish SPresident and CEO | SSale | −25.0K | $308.12 | −$7.70M | −1.7%1.45M after | 11 lots10b5-1 |
| May 27, 2026 (view filing) | May 26 | 1 day | Thomas John CharlesEVP, General Counsel | SSale | −642 | $302.03 | −$193.9K | −100.0%0 after | 10b5-1 |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Krishnan SumaPresident, R&D | SSale | −25.0K | $263.21 | −$6.58M | −1.8%1.40M after | 10 lots10b5-1 |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Krishnan Krish SPresident and CEO | SSale | −25.0K | $263.17 | −$6.58M | −1.7%1.48M after | 10 lots10b5-1 |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Romano KathrynChief Accounting Officer | SSale | −750 | $267.60 | −$200.7K | −3.2%22.4K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 424 holdersThe largest institutional positions in Krystal Biotech, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 4,418,197 | $1.64B | 0.07% | +44,210+1.0% | Added |
| BlackRock, Inc. | 4,181,432 | $1.55B | 0.02% | +240,976+6.1% | Added |
| Avoro Capital Advisors LLC | 2,888,888 | $1.07B | 9.64% | 00.0% | Unchanged |
| Vanguard Portfolio Management LLC | 1,574,905 | $585.3M | 0.03% | +118,178+8.1% | Added |
| State Street Corp | 1,351,158 | $502.2M | 0.01% | +36,724+2.8% | Added |
| Vanguard Capital Management LLC | 1,240,567 | $461.1M | 0.01% | +75,243+6.5% | Added |
| Soleus Capital Management, L.P. | 939,254 | $349.1M | 12.03% | −213,833−18.5% | Reduced |
| Capital World Investors | 777,843 | $289.1M | 0.03% | −46,877−5.7% | Reduced |
| Geode Capital Management, LLC | 698,993 | $259.8M | 0.01% | +55,018+8.5% | Added |
| Price T Rowe Associates Inc | 687,400 | $255.5M | 0.03% | +202,326+41.7% | Added |
Holders of 5% or more of KRYS
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Krystal Biotech, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 11.60%3.43M shares | – | Oct 27, 20261 filing | Oct 27, 2026 | SEC |
| Krishnan Krish S | 13G/A | 11.50%3.39M shares | – | May 4, 20261 filing | May 4, 2026 | SEC |
Politician trades
All politician trades in KRYS1 member of Congress reported 1 trade in Krystal Biotech, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Jan 20, 2023 |  Chris Jacobs House · NY | Buy | $1K-$15K |
House · NY · Jan 20, 2023
Buy$1K-$15K